Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Modeling Outcomes of First-Line Antiretroviral Therapy and Rate of CD4 Counts Change among a Cohort of HIV/AIDS Patients in Ethiopia: A Retrospective Cohort Study.

Awoke T, Worku A, Kebede Y, Kasim A, Birlie B, Braekers R, Zuma K, Shkedy Z.

PLoS One. 2016 Dec 20;11(12):e0168323. doi: 10.1371/journal.pone.0168323. eCollection 2016.

2.

The Global Health Impact Index: Promoting Global Health.

Hassoun N.

PLoS One. 2015 Dec 11;10(12):e0141374. doi: 10.1371/journal.pone.0141374. eCollection 2015. Erratum in: PLoS One. 2016;11(2):e0148946.

3.

Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort.

Scarsi KK, Eisen G, Darin KM, Meloni ST, Rawizza HE, Tchetgen Tchetgen EJ, Agbaji OO, Onwujekwe DI, Gashau W, Nkado R, Okonkwo P, Murphy RL, Kanki PJ; Harvard/APIN PEPFAR Team.

Clin Infect Dis. 2016 Feb 15;62(4):512-8. doi: 10.1093/cid/civ928. Epub 2015 Nov 10.

4.

Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).

Touzard Romo F, Smeaton LM, Campbell TB, Riviere C, Mngqibisa R, Nyirenda M, Supparatpinyo K, Kumarasamy N, Hakim JG, Flanigan TP.

HIV Clin Trials. 2014 Nov-Dec;15(6):246-60. doi: 10.1310/hct1506-246.

5.

The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa.

Shearer K, Fox MP, Maskew M, Berhanu R, Long L, Sanne I.

PLoS One. 2013 Aug 7;8(8):e71719. doi: 10.1371/journal.pone.0071719. Print 2013.

6.

Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens.

Van Zyl GU, Liu TF, Claassen M, Engelbrecht S, de Oliveira T, Preiser W, Wood NT, Travers S, Shafer RW.

PLoS One. 2013 Jun 26;8(6):e67188. doi: 10.1371/journal.pone.0067188. Print 2013.

7.

Deficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review.

Hernandez AV, Pasupuleti V, Deshpande A, Thota P, Collins JA, Vidal JE.

PLoS One. 2013 May 3;8(5):e63272. doi: 10.1371/journal.pone.0063272. Print 2013. Review.

8.

Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment.

Yone EW, Kengne AP.

HIV AIDS (Auckl). 2012;4:181-4. doi: 10.2147/HIV.S24432. Epub 2012 Dec 5.

9.

A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.

Phanuphak N, Ananworanich J, Teeratakulpisarn N, Jadwattanakul T, Kerr SJ, Chomchey N, Hongchookiat P, Mathajittiphun P, Pinyakorn S, Rungrojrat P, Praihirunyakit P, Gerschenson M, Phanuphak P, Valcour V, Kim JH, Shikuma C; SEARCH 003 Study Group.

Antivir Ther. 2012;17(8):1521-31. doi: 10.3851/IMP2497. Epub 2012 Dec 7.

10.

Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.

Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, Chipato T, Asmelash A, Rassool M, Kimaiyo S, Shaffer D, Hosseinipour M, Mohapi L, Ssali F, Chibowa M, Amod F, Halvas E, Hogg E, Alston-Smith B, Smith L, Schooley R, Mellors J, Currier J; OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG A5208/OCTANE Study Team.

PLoS Med. 2012;9(6):e1001236. doi: 10.1371/journal.pmed.1001236. Epub 2012 Jun 12.

11.

Least among equals.

Kuritzkes DR, Hakim JG, Sanne I.

Clin Infect Dis. 2012 Mar;54(6):876-7. doi: 10.1093/cid/cir1048. No abstract available.

12.

A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.

Tang MW, Kanki PJ, Shafer RW.

Clin Infect Dis. 2012 Mar;54(6):862-75. doi: 10.1093/cid/cir1034. Review.

13.

Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.

Chi BH, Mwango A, Giganti MJ, Sikazwe I, Moyo C, Schuttner L, Mulenga LB, Bolton-Moore C, Chintu NT, Sheneberger R, Stringer EM, Stringer JS.

J Acquir Immune Defic Syndr. 2011 Dec 15;58(5):475-81. doi: 10.1097/QAI.0b013e31823058a3.

14.

Antiretroviral therapies in women after single-dose nevirapine exposure.

Lockman S, Hughes MD, McIntyre J, Zheng Y, Chipato T, Conradie F, Sawe F, Asmelash A, Hosseinipour MC, Mohapi L, Stringer E, Mngqibisa R, Siika A, Atwine D, Hakim J, Shaffer D, Kanyama C, Wools-Kaloustian K, Salata RA, Hogg E, Alston-Smith B, Walawander A, Purcelle-Smith E, Eshleman S, Rooney J, Rahim S, Mellors JW, Schooley RT, Currier JS; OCTANE A5208 Study Team.

N Engl J Med. 2010 Oct 14;363(16):1499-509. doi: 10.1056/NEJMoa0906626.

15.

Economic evaluation of ART in resource-limited countries.

Loubiere S, Meiners C, Sloan C, Freedberg KA, Yazdanpanah Y.

Curr Opin HIV AIDS. 2010 May;5(3):225-31. doi: 10.1097/COH.0b013e3283384a9d. Review.

16.

Supplemental Content

Support Center